BLA 125513 · Alexion Pharm
Strensiq
Asfotase Alfa · Injection · Tissue-nonspecific Alkaline Phosphatase
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Oct 23, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
16
4 Phase 3, 1 recruiting
FAERS reports
10,322
3,394 serious, 79 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate STRENSIQ under the supervision of a healthcare provider with appropriate medical monitoring and support measures. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue STRENSIQ and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full prescribing information...
What it is approved for
From the label in effect Dec 12, 2025.
STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). STRENSIQ is a tissue nonspecific alkaline phosphatase indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). ( 1 )
Mechanism: HPP is caused by a deficiency in TNSALP enzyme activity, which leads to elevations in several TNSALP substrates, including inorganic pyrophosphate (PPi). TNSALP is a metallo-enzyme that catalyzes the hydrolysis of phosphomonoesters with release of inorganic phosphate and alcohol. Elevated extracellular levels of PPi block hydroxyapatite crystal growth which inhibits bone mineralization and causes an accumulation of unmineralized bone matrix which manifests as rickets and bone deformation in infants and children and as osteomalacia (softening of bones) once growth plates close, along with...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 2020 Supplement 18 · Efficacy OrphanLabelLetter
- Oct 23, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelSummary ReviewReview
4 products under this application
- STRENSIQ · ASFOTASE ALFA 80MG/0.8ML · SOLUTION, INJECTION · Prescription
- STRENSIQ · ASFOTASE ALFA 28MG/0.7ML · SOLUTION, INJECTION · Prescription
- STRENSIQ · ASFOTASE ALFA 40MG/ML · SOLUTION, INJECTION · Prescription
- STRENSIQ · ASFOTASE ALFA 18MG/0.45ML · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Asfotase Alfa" as an intervention, any sponsor and status, largest first.
- Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase AlfaPivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06079281 · 124 participants · Start Jan 3, 2024 · Primary completion Jul 9, 2025
Drug: ALXN1850; Placebo · For: Hypophosphatasia
Sites: Indianapolis, Indiana; Garden City, New York; Durham, North Carolina · 65 sites in all
- Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)Pivotal-lookingCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT01176266 · 69 participants · Start Jul 2010 · Primary completion Sep 2016
Drug: asfotase alfa · For: Hypophosphatasia
Sites: Oakland, California; Cincinnati, Ohio; Pittsburgh, Pennsylvania · 23 sites in all
- Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase AlfaPivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06079372 · 43 participants · Start Apr 2, 2024 · Primary completion Jul 23, 2025
Drug: ALXN1850; asfotase alfa · For: Hypophosphatasia
Sites: Hartford, Connecticut; Baltimore, Maryland; Minneapolis, Minnesota · 21 sites in all
- Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPPPivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06079359 · 30 participants · Start May 14, 2024 · Primary completion Jan 6, 2026
Drug: ALXN1850; Placebo · For: Hypophosphatasia
Sites: Baltimore, Maryland; Kansas City, Missouri; Durham, North Carolina · 32 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT02797821 · 27 participants · Start Jun 6, 2016 · Primary completion Jun 21, 2017
Drug: Asfotase alfa · For: Hypophosphatasia
Sites: St Louis, Missouri; Durham, North Carolina; Nashville, Tennessee · 4 sites in all
- Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)Completed
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT01163149 · 19 participants · Start Jun 2010 · Primary completion Jun 2016
Drug: asfotase alfa; asfotase alfa · For: Hypophosphatasia
Sites: St Louis, Missouri; Durham, North Carolina; Winnipeg, Canada
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT02531867 · 13 participants · Start Jun 2015 · Primary completion Nov 2015
Drug: Asfotase Alfa · For: Hypophosphatasia
Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanAcademic, hospital or other
NCT02456038 · 13 participants · Start Aug 2014 · Primary completion Jul 2015
Drug: Asfotase Alfa (ALXN1215) · For: Hypophosphatasia
Sites: Kurume, Japan; Gifu, Japan; Hiroshima, Japan · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site pain1,351
- fatigue1,029
- injection site erythema881
- pain851
- injection site reaction778
- arthralgia713
- pain in extremity564
- injection site bruising513
- injection site swelling442
- headache416
- injection site pruritus344
- bone pain323
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 33 |
| 2016 | 785 |
| 2017 | 1,088 |
| 2018 | 1,301 |
| 2019 | 1,057 |
| 2020 | 259 |
| 2021 | 206 |
| 2022 | 172 |
| 2023 | 714 |
| 2024 | 2,432 |
| 2025 | 1,084 |
| 2026 | 1,191 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Strensiq (Asfotase Alfa)
2024 spending
$346M
Beneficiaries
290
3,431 claims
Per beneficiary
$1,193,004
$6,147.95 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $139,626,523 |
| 2021 | $179,636,998 |
| 2022 | $220,781,958 |
| 2023 | $258,940,106 |
| 2024 | $345,971,144 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial.
Whyte MP, Simmons JH, Moseley S, et al. · Lancet Diabetes Endocrinol 2019 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review.
Shirinezhad A, Esmaeili S, Azarboo A, et al. · Bone 2024 · Systematic Review
- Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA's Health Technology Assessments.
Wagle JA, Flacke JP, Knoerzer D, et al. · Value Health 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia.
Dahir KM, Shannon A, Dunn D, et al. · J Bone Miner Res 2024 · Clinical Trial, Phase I, Multicenter Study
- Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
Kishnani PS, Rockman-Greenberg C, Rauch F, et al. · Bone 2019 · Clinical Trial, Phase II, Randomized Controlled Trial
- Ectopic Ocular Surface Calcification in Patients With Hypophosphatasia Treated With Asfotase Alfa.
Gospe SM, Santiago-Turla C, DeArmey SM, et al. · Cornea 2019 · Randomized Controlled Trial
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.